Advertisement
YOU ARE HERE: LAT HomeCollectionsRoche Holding Ltd
IN THE NEWS

Roche Holding Ltd

BUSINESS
June 9, 1990 | MARTHA GROVES, TIMES STAFF WRITER
Shareholders of biotechnology pioneer Genentech voted overwhelmingly Friday to approve the company's $2.1-billion merger with Roche Holding, a Swiss pharmaceutical giant, despite last-ditch efforts by disgruntled longtime investors to derail the plan. At the end of a rancorous annual meeting in Millbrae, south of San Francisco, the company said 97% of those voting favored the deal.
Advertisement
BUSINESS
December 15, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Consolidation in the $30-billion medical-testing business accelerated Wednesday as La Jolla-based National Health Laboratories and Swiss-owned Roche Biomedical Laboratories said they would merge into the nation's largest diagnostic laboratory chain. Company officials and analysts said the merger idea was a response to intense price pressure coming from cost-conscious managed-care firms and the federal government. The combination of the third-largest and fourth-largest U.S.
BUSINESS
November 17, 2003 | Denise Gellene, Times Staff Writer
What is now a contest between Amgen Inc. and Johnson & Johnson over the lucrative anemia drug business could soon become a three-way race. At a medical meeting here this weekend, Swiss drug maker Roche said it was ready to begin the final round of human tests needed for government approval of Cera, its investigational anemia drug.
BUSINESS
March 5, 2008 | From Reuters
Roche Holding and GlaxoSmithKline said Tuesday that they had added new labels to their prescription flu medicines that contain reports of abnormal psychiatric behavior in some patients. A warning about cases of delirium and unusual behavior had been listed previously on Roche's drug, Tamiflu. That language was strengthened to say some cases were fatal.
BUSINESS
May 26, 1999 | From Bloomberg News
Roche Holding and BASF, which last week agreed to pay record U.S. fines totaling $725 million for conspiring to fix global vitamin prices, may also face stiff European Union fines, EU Competition Commissioner Karel Van Miert suggested. A resolution to the EU's own investigation is still months away, however, and Van Miert would not say which companies the EU may fine. Roche, Europe's fourth-biggest drug maker, agreed last week to pay $500 million--the largest U.S.
BUSINESS
August 29, 2001 | Reuters
Swiss pharmaceuticals giant Roche Holding denied it held talks with Bayer about buying its drug business, though one source who has been in touch with Bayer management said it had made a preliminary approach. Roche said reports it was a possible buyer of Bayer or its pharmaceuticals business have no basis in fact.
BUSINESS
December 13, 2005 | From Associated Press
Swiss drug maker Roche Holding said it had chosen 12 potential partners for the production of Tamiflu and granted one sub-license for the antiviral drug to Shanghai Pharmaceutical. Basel-based Roche said it had compiled the short list of potential partners, which it did not identify, after evaluating about 200 applicants interested in helping with certain steps in the manufacturing of Tamiflu. It didn't say how many it would finally choose.
BUSINESS
October 21, 2006 | From Bloomberg News
Amgen Inc. can pursue a patent lawsuit that seeks to block Roche Holding from selling the anemia drug Cera in the U.S., a judge ruled Friday, agreeing to a timetable that may lead to a trial as early as May. U.S. District Judge William G. Young in Boston rejected Roche's request that the suit be thrown out because Cera isn't yet sold in the U.S. The Food and Drug Administration may decide in February whether to approve the drug, used to boost red blood cells, Amgen said.
BUSINESS
May 23, 2003 | From Bloomberg News
Roche Holding said it may pay Maxygen Inc. more than $230 million as part of a research agreement for hepatitis medicines. The deal gives Roche worldwide marketing rights to potential treatments for hepatitis B and C, the Swiss company said. Redwood City, Calif.-based Maxygen will get research and development funding for the first two years, as well as royalties and payments when development goals are met. Shares of Maxygen jumped $1.55 to $9.66 on Nasdaq.
BUSINESS
August 27, 2002 | Bloomberg News
Roche Holding, which is trying to revive demand for its Xenical obesity pill, said the medicine may delay or prevent the development of the most common form of diabetes. Patients taking Xenical who also made lifestyle changes reduced their risk of developing diabetes by 37%, a four-year study sponsored by Roche showed. Switzerland's second-biggest drug maker has changed its marketing for the pill and now offers three months of the medicine free to U.S. patients who purchase three months' worth.
Los Angeles Times Articles
|